biostudies-literatureFiocchi AGRegeneron PharmaceuticalsSanofi2300558https://www.ebi.ac.uk/biostudies/studies/S-EPMC10620476biostudies-literatureUnknown62(5)<h4>Background</h4>Dupilumab has shown long-term treatment benefits in children with uncontrolled asthma. We assessed in more detail the impact of dupilumab on asthma control and health-related quality of life (HRQoL) in children and their caregivers.<h4>Methods</h4>Children aged 6-11 years with uncontrolled moderate-to-severe type 2 asthma (baseline blood eosinophils ≥150 cells·µL^-1 or fractional exhaled nitric oxide ≥20 ppb; n=350) were treated with dupilumab or placebo for 52 weeks in the VOYAGE study. Primary outcomes of these analyses were asthma control (change from baseline in Asthma Control Questionnaire 7 Interviewer-Administered (ACQ-7-IA) and achieving a clinically meaningful response of ≥0.5 points); proportion of patients achieving well-controlled asthma or better (The European respiratory journalDupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study.PMC10620476NCT02948959Lederer DJKhan AHRowe PJCole JDurrani SRZeiger RSHardin MFiocchi AGMsihid JZhang YDeniz YJacob-Nara JAPhipatanakul WGall RfalseDupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study.<h4>Background</h4>Dupilumab has shown long-term treatment benefits in children with uncontrolled asthma. We assessed in more detail the impact of dupilumab on asthma control and health-related quality of life (HRQoL) in children and their caregivers.<h4>Methods</h4>Children aged 6-11 years with uncontrolled moderate-to-severe type 2 asthma (baseline blood eosinophils ≥150 cells·µL^-1 or fractional exhaled nitric oxide ≥20 ppb; n=350) were treated with dupilumab or placebo for 52 weeks in the VOYAGE study. Primary outcomes of these analyses were asthma control (change from baseline in Asthma Control Questionnaire 7 Interviewer-Administered (ACQ-7-IA) and achieving a clinically meaningful response of ≥0.5 points); proportion of patients achieving well-controlled asthma or better (2023-01-01T00:00:00Z2023 Nov2026-06-11T05:54:27.514Z2025-04-05T13:01:31.498ZS-EPMC106204763773485610.1183/13993003.00558-2023